Therapeutic effects of catechins in less common neurological and neurodegenerative disorders
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Sebastiani, Giorgia
- dc.contributor.author Almeida Toledano, Laura
- dc.contributor.author Serra Delgado, Mariona
- dc.contributor.author Navarro-Tapia, Elisabet
- dc.contributor.author Sailer, Sebastian
- dc.contributor.author Valverde Granados, Olga
- dc.contributor.author García Algar, Oscar
- dc.contributor.author Andreu Fernández, Vicente
- dc.date.accessioned 2021-08-24T06:51:19Z
- dc.date.available 2021-08-24T06:51:19Z
- dc.date.issued 2021
- dc.description.abstract In recent years, neurological and neurodegenerative disorders research has focused on altered molecular mechanisms in search of potential pharmacological targets, e.g., imbalances in mechanisms of response to oxidative stress, inflammation, apoptosis, autophagy, proliferation, differentiation, migration, and neuronal plasticity, which occur in less common neurological and neurodegenerative pathologies (Huntington disease, multiple sclerosis, fetal alcohol spectrum disorders, and Down syndrome). Here, we assess the effects of different catechins (particularly of epigalocatechin-3-gallate, EGCG) on these disorders, as well as their use in attenuating age-related cognitive decline in healthy individuals. Antioxidant and free radical scavenging properties of EGCG -due to their phenolic hydroxyl groups-, as well as its immunomodulatory, neuritogenic, and autophagic characteristics, makes this catechin a promising tool against neuroinflammation and microglia activation, common in these pathologies. Although EGCG promotes the inhibition of protein aggregation in experimental Huntington disease studies and improves the clinical severity in multiple sclerosis in animal models, its efficacy in humans remains controversial. EGCG may normalize DYRK1A (involved in neural plasticity) overproduction in Down syndrome, improving behavioral and neural phenotypes. In neurological pathologies caused by environmental agents, such as FASD, EGCG enhances antioxidant defense and regulates placental angiogenesis and neurodevelopmental processes. As demonstrated in animal models, catechins attenuate age-related cognitive decline, which results in improvements in long-term outcomes and working memory, reduction of hippocampal neuroinflammation, and enhancement of neuronal plasticity; however, further studies are needed. Catechins are valuable compounds for treating and preventing certain neurodegenerative and neurological diseases of genetic and environmental origin. However, the use of different doses of green tea extracts and EGCG makes it difficult to reach consistent conclusions for different populations.
- dc.format.mimetype application/pdf
- dc.identifier.citation Sebastiani G, Almeida-Toledano L, Serra-Delgado M, Navarro-Tapia E, Sailer S, Valverde O, Garcia-Algar O, Andreu-Fernández V. Therapeutic effects of catechins in less common neurological and neurodegenerative disorders. Nutrients. 2021;13(7):2232. DOI: 10.3390/nu13072232
- dc.identifier.doi http://dx.doi.org/10.3390/nu13072232
- dc.identifier.issn 2072-6643
- dc.identifier.uri http://hdl.handle.net/10230/48325
- dc.language.iso eng
- dc.publisher MDPI
- dc.relation.ispartof Nutrients. 2021;13(7):2232
- dc.rights © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by/4.0/
- dc.subject.keyword Down syndrome
- dc.subject.keyword Age-related cognitive decline
- dc.subject.keyword Antioxidant
- dc.subject.keyword Catechins
- dc.subject.keyword Epigallocatechin-3-gallate
- dc.subject.keyword Fetal alcohol spectrum disorders
- dc.subject.keyword Multiple sclerosis
- dc.subject.keyword Neurodegenerative disorders
- dc.subject.keyword Neurological disorders
- dc.title Therapeutic effects of catechins in less common neurological and neurodegenerative disorders
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion